Cytomx Thera (CTMX) Stock Price, Quote & News

Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index f...

Industry: Biotechnology

Sector: Healthcare

Phone: (650) 515-3185

Fax: (650) 351-0353

Website: www.cytomx.com

Address:

151 Oyster Point Boulevard, Suite 400, South San Francisco, United States

deerix Jul. 8 at 3:19 AM

$VOR is 1400% a lot or not? Follow or miss out next time, it's up to you. ✅️🫱🫲 Killing it for the last few months. $CTMX $SPY

1 · Reply

PleadNoContest Jul. 7 at 11:51 PM

$CTMX Stop it TACO.

0 · Reply

HTNY Jul. 7 at 11:48 PM

$DAVE $ARQ $TOYO $CTMX $CCLD All of these have been superb. No pump and dumps, just good DD and confident buying and holding. I averaged up on all of these. Never afraid to do that on stocks that I see as materially undervalued. More to come.

0 · Reply

deerix Jul. 7 at 2:09 PM

$VOR $CTMX 1250% and counting... ✅️⚠️

1 · Reply

PleadNoContest Jul. 5 at 10:49 PM

$CTMX ...Holiday weekend. Burgers etc

0 · Reply

Korrok_Soy_Sauce Jul. 5 at 1:14 PM

$CTMX very quiet board

0 · Reply

MicahbRr Jul. 4 at 12:59 AM

$CTMX Yo @Sagacious99 , hype like that require links brother man. For me that’s just common courtesy😜

0 · Reply

Sagacious99 Jul. 3 at 10:47 PM

$CTMX Trodelvy plus Keytruda combo therapy approved! Cx-2051 will work with Keytruda as well! Expect Merck to expand the partnership. Cx2051 ADC will do better in TnBC than Trodelvy TnBC has a larger expression of Epcam than Trop2. Blockbuster drug.

1 · Reply

Salchicha Jul. 3 at 2:03 PM

$CTMX a buyout will be nice i will guess around $10 per share.

1 · Reply

AKnee Jul. 3 at 11:23 AM

$CTMX BVF’s 2025 tranche warrants at adjusted exercise price of $2.73 after recent offering expire today. I don’t believe they had an opportunity to sell all 5.7M shares between 2.73 and 3.10 because the trading volume wasn't large enough during that time period when stock recently traded up there. Keep an eye out for an SEC filing coming out soon. Im guessing they exercise all of these warrants without letting any expire which shows even more strength and confidence in their current almost 10% of float investment

0 · Reply

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 7 weeks ago

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

May 13, 2025, 10:34 AM EDT - 7 weeks ago

CytomX Therapeutics: Doubling Overnight On Phase 1 Data

May 12, 2025, 2:40 PM EDT - 2 months ago

CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)

May 12, 2025, 11:11 AM EDT - 2 months ago

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

May 12, 2025, 6:50 AM EDT - 2 months ago

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

May 12, 2025, 6:15 AM EDT - 2 months ago

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

May 12, 2025, 6:15 AM EDT - 2 months ago

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:00 AM EDT - 2 months ago

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 28, 2025, 4:00 PM EDT - 2 months ago

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

Mar 6, 2025, 6:34 PM EST - 4 months ago

CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:10 PM EST - 4 months ago

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 4 months ago

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 4 months ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Jan 6, 2025, 4:05 PM EST - 6 months ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

Nov 27, 2024, 8:00 AM EST - 7 months ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 8, 2024, 8:44 AM EST - 8 months ago

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:10 PM EST - 8 months ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 9, 2024, 8:00 AM EDT - 10 months ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Aug 8, 2024, 4:10 PM EDT - 11 months ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 17, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

May 16, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces New Employment Inducement Grants

May 9, 2024, 9:10 AM EDT - 1 year ago

CytomX stock down 30% despite encouraging cancer study results

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

May 7, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

May 1, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

Apr 25, 2024, 6:33 PM EDT - 1 year ago

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 8, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

Apr 3, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 21, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Mar 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 11, 2024, 6:39 PM EDT - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript

Mar 11, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 4, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Feb 27, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at Upcoming March Investor Conferences

Jan 24, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

Jan 12, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

Jan 4, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

Dec 21, 2023, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 2:32 AM EST - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:15 PM EST - 1 year ago

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 1, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at Upcoming November Investor Conferences

Oct 31, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

Oct 30, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

Oct 18, 2023, 4:30 PM EDT - 1 year ago

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

Sep 5, 2023, 4:05 PM EDT - 1 year ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Aug 10, 2023, 4:05 PM EDT - 2 years ago

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

Aug 8, 2023, 10:57 PM EDT - 2 years ago

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

deerix Jul. 8 at 3:19 AM

$VOR is 1400% a lot or not? Follow or miss out next time, it's up to you. ✅️🫱🫲 Killing it for the last few months. $CTMX $SPY

1 · Reply

PleadNoContest Jul. 7 at 11:51 PM

$CTMX Stop it TACO.

0 · Reply

HTNY Jul. 7 at 11:48 PM

0 · Reply

deerix Jul. 7 at 2:09 PM

$VOR $CTMX 1250% and counting... ✅️⚠️

1 · Reply

PleadNoContest Jul. 5 at 10:49 PM

$CTMX ...Holiday weekend. Burgers etc

0 · Reply

Korrok_Soy_Sauce Jul. 5 at 1:14 PM

$CTMX very quiet board

0 · Reply

MicahbRr Jul. 4 at 12:59 AM

$CTMX Yo @Sagacious99 , hype like that require links brother man. For me that’s just common courtesy😜

0 · Reply

Sagacious99 Jul. 3 at 10:47 PM

1 · Reply

Salchicha Jul. 3 at 2:03 PM

$CTMX a buyout will be nice i will guess around $10 per share.

1 · Reply

AKnee Jul. 3 at 11:23 AM

0 · Reply

AKnee Jul. 3 at 10:33 AM

$CTMX 21M share short, 14% of float. Great Phase 1 results with more upside potential within 6months to 1 year. Pipeline filled with reputable big bio partners who could easily buy them out. Smart money institutions recently invested in the capital raise (Same ones that invested in IMMU, taken over by Gilead for 88/share. Happy I repositioned even larger after this recent retracement after my profit taking sales at $2.95. Major short squeeze potential on horizon

1 · Reply

Perillo1983 Jul. 3 at 1:43 AM

$CTMX 👏👏👏$$$$$

0 · Reply

MichaelSctock Jul. 2 at 8:39 PM

$CTMX quick 10% here 🍻 but that 100k before close tells me…more coming 😁

1 · Reply

Turdsniffer Jul. 2 at 4:29 PM

$CTMX low volume today. Probably gonna get dumped on at bell🤷🏻‍♂️..

0 · Reply

deerix Jul. 2 at 2:56 PM

$VOR $CTMX That's 800%+ you are welcome

1 · Reply

Turdsniffer Jul. 2 at 2:26 PM

$CTMX whoa

0 · Reply

Perillo1983 Jul. 2 at 12:04 PM

$CTMX Earnings in about 5 weeks may get news leading up to it! This company is dirt cheap stars are starting to align!! This is a $10 stock going into 2026 still flying under the radar!! 👏👏👏👏😜👇

0 · Reply

Rick2058 Jul. 2 at 11:29 AM

$CTMX Rick2058 Jun 27, 2025 12:18 PM $CTMX Americanbulls reversal imminent, BUY level of 2.32 maintained to close will confirm. May attract interest. Also Barchart #3 on list of Top Stocks Under $10. Bullish Reversal confirmed BUY level met.

0 · Reply

Perillo1983 Jul. 1 at 11:47 PM

$CTMX News tomorrow??

0 · Reply

Salchicha Jul. 1 at 8:12 PM

$CTMX 🧨🚀🚀🚀

0 · Reply

bryantboy99 Jul. 1 at 8:00 PM

$CTMX strong close

2 · Reply

PleadNoContest Jul. 1 at 7:31 PM

$CTMX Here come the ffeggut shorts to sell off the pennies.

1 · Reply

Market Cap	201.55M
Revenue (ttm)	138.10M
Net Income (ttm)	31.87M
EPS (ttm)	N/A
PE Ratio	5.17
Forward PE	N/A
Profit Margin	23.08%
Debt to Equity Ratio	0.00

Volume	1,993,300
Avg Vol	6,052,578
Day's Range	N/A - N/A
Shares Out	80.62M
Stochastic %K	65%
Beta	2.05
Analysts	Strong Sell
Price Target	$5.20